We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Flow Cytometric Assay Evaluated for Heparin-Induced Thrombocytopenia

By LabMedica International staff writers
Posted on 05 Jul 2016
Heparin-induced thrombocytopenia (HIT) is an immune-mediated thrombocytopenia associated with heparin therapy and the diagnosis consists of a combination of pretest probability and laboratory testing.

The routinely available laboratory antigen binding assays for the detection of specific antibodies have a low HIT-positive predictive value; therefore, to exclude false-positive results, one of the functional assays should be performed. More...
Functional assays evaluate the ability of heparin/platelet factor 4 (PF4) antibodies to activate the platelets.

Scientists at the University Medical Centre Ljubljana (Slovenia) investigated sera from adult patients, in which HIT was suspected, for the presence of HIT antibodies, using an immunoglobulin G enzyme-linked immunosorbent assay (IgG-ELISA) as the laboratory standard practice. After they set up the functional assay, 41 ELISA-positive serum samples were collected randomly for further testing.

The team tested the sera using an IgG-specific ELISA Kit (GTI Diagnostics, Inc., Waukesha, WI, USA). Platelet-activating antibodies were detected with a functional flow cytometric assay and analyzed on a FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). A functional heparin-induced platelet aggregation assay (HIPA) was also performed. Each test included diluted serum from the HIT patients as weak positive controls and serum from healthy donors as negative controls. To set up the cutoff of the flow cytometric assay, they analyzed a total of 100 samples, 25 HIT-positive and HIT-negative sera, each tested with different donor platelets.

The scientists found that of 41 ELISA positive serum samples, 14 were positive and 20 were negative by both flow cytometer and HIPA. Three other samples were discrepant between two assays: they were HIPA-positive and were negative with the flow cytometric assay. Conversely, four samples were flow cytometer positive and HIPA-negative. The samples included in this comparison were sera with detected anti-heparin/PF4 IgG antibodies with an OD greater than 0.4. The diagnostic specificity of the flow cytometric assay was calculated based on HIPA results and was 83%.

The authors concluded that performing this functional test after the screening assay could significantly improve the specificity of HIT testing as heparin/PF4 antibodies are often not clinically significant. The study was published in the June 2016 edition of the International Journal of Laboratory Hematology.

Related Links:
University Medical Centre Ljubljana
GTI Diagnostics
Becton Dickinson

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Automatic CLIA Analyzer
Shine i6000
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.